[HTML][HTML] Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies, GM Pupo… - Nature …, 2014 - nature.com
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and
MEK inhibition progress within 6 months. Treatment options for these patients remain …
MEK inhibition progress within 6 months. Treatment options for these patients remain …
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies… - Nature …, 2014 - econpapers.repec.org
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and
MEK inhibition progress within 6 months. Treatment options for these patients remain …
MEK inhibition progress within 6 months. Treatment options for these patients remain …
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
GV Long, C Fung, AM Menzies, GM Pupo… - Nature …, 2014 - europepmc.org
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and
MEK inhibition progress within 6 months. Treatment options for these patients remain …
MEK inhibition progress within 6 months. Treatment options for these patients remain …
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies… - Nature …, 2014 - pubmed.ncbi.nlm.nih.gov
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and
MEK inhibition progress within 6 months. Treatment options for these patients remain …
MEK inhibition progress within 6 months. Treatment options for these patients remain …
[PDF][PDF] Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies, GM Pupo… - NATURE …, 2014 - academia.edu
Results Patients and melanoma tissue samples. Eleven Prog and nine matched pre-
treatment melanoma tumour samples derived from 10 BRAFV600-mutant melanoma …
treatment melanoma tumour samples derived from 10 BRAFV600-mutant melanoma …
[引用][C] Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies, GM Pupo… - Nature …, 2014 - cir.nii.ac.jp
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy
of BRAF-mutant metastatic melanoma | CiNii Research CiNii 国立情報学研究所 学術情報 …
of BRAF-mutant metastatic melanoma | CiNii Research CiNii 国立情報学研究所 学術情報 …
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies… - Nature …, 2014 - ui.adsabs.harvard.edu
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and
MEK inhibition progress within 6 months. Treatment options for these patients remain …
MEK inhibition progress within 6 months. Treatment options for these patients remain …
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies… - Nature …, 2014 - researchers.mq.edu.au
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and
MEK inhibition progress within 6 months. Treatment options for these patients remain …
MEK inhibition progress within 6 months. Treatment options for these patients remain …
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies, GM Pupo… - Nature …, 2014 - ideas.repec.org
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and
MEK inhibition progress within 6 months. Treatment options for these patients remain …
MEK inhibition progress within 6 months. Treatment options for these patients remain …
[PDF][PDF] Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies, GM Pupo… - NATURE …, 2014 - scholar.archive.org
Results Patients and melanoma tissue samples. Eleven Prog and nine matched pre-
treatment melanoma tumour samples derived from 10 BRAFV600-mutant melanoma …
treatment melanoma tumour samples derived from 10 BRAFV600-mutant melanoma …